Neev Mehta

Finally someone’s done this study pubmed.ncbi.nlm.nih.gov/41482657/

Prophylaxis of SBP is dying But if you still insist, then please do NOT continue the same antibiotic after an episode of SBP. This happens 80% of the time according to a new study. Bananas!!! Just because cipro is in the guidelines does not mean it’s the only one you can use.

Cirrhosis is diagnosed too late. Routine ECG + AI can do more than assess the heart in primary care, now in @NatureMedicine 🫀15,596 patients with ECG 🏥Pragmatic randomized trial 📈Increased detection of liver disease 💡Scalable, low-cost screening nature.com/articles/s4159…

Data are very weak. doi.org/10.1093/cid/ci…

Loved interacting with residents and diving into all things endoscopy! Thank you @AmCollegeGastro @IBD_Afzali for the opportunity! #GITwitter #MedTwitter #ACG2025

The tradition continues! 
✅ ACG 2022
✅ ACG 2024
✅ ACG 2025 Grateful for another incredible #ACG experience — learning, connecting, and being inspired by the brightest minds in GI. Leaving more empowered and motivated than ever! #Gastroenterology #MedTwitter #ACG2025

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine nejm.org/doi/full/10.10…

Perioperative risk assessment and management in patients with cirrhosis: new clinical guidelines from @AmCollegeGastro 🆕✂️ 📸: journals.lww.com/ajg/fulltext/2…

🧬 Early is Better in Crohn’s Disease! A new multicenter study shows starting biologic therapy within 12 months of Crohn’s diagnosis significantly boosts transmural healing (TH)—a deeper healing target linked to better long-term outcomes. 🔹 TH rates tripled with early biologics (aOR 3.2) 🔹 Lower risk of: – Bowel damage (aHR 0.28) – Surgery (aHR 0.21) – Therapy escalation (aHR 0.35) 📊 TH = full normalization on MRI, beyond just mucosal healing. 📅 Timing matters. Aim for <12 months from diagnosis. 📍 Let’s rethink our treatment targets. 🩻 Treat early. Heal deep. Change the trajectory. @IBD_Afzali @IBDProNews @DCharabaty @AmerGastroAssn @AGA_CGH @IBD_FloMD cghjournal.org/article/S1542-…

Cardiovascular risk estimates miss the mark in people with MASH Heart disease is the most important risk for patients with MASH but the commonly used risk equations just don’t work New paper in @AmJGastro

Excited to announce results of our #ADDapt trial After 6 years and the help of 154 people with #CrohnsDisease we prove that restricting #emulsifiers improves disease Award winning presentation from @AaronBancil at #ECCO25 Excited for next steps to help people with Crohns

.@HopkinsGIHep Colorado GI course #DrBlairFennimore ⚠️Treat #ASUC ASAP ✅CRP, biologic pre-rec, serum CMV PCR, CDiff, X-ray, Flex sig ✅Surgery if toxic megacolon, severe🩸, perf, non-compliance ✅If Predictors of steroid failure on D1 & D3 of steroids- 🤔advanced Rx or ✂️early

What a day in the history of MASH! Reversal of Fibrosis in MASH cirrhotics by 24% (paired) and 17% (ITT) all sig P values. Same for NITs!!!! Happy for the our patients. FGF21s are here to stay!! #livertwitter @ebtapper @AlkhouriNaim @akerotx globenewswire.com/news-release/2…

.@HopkinsGIHep Colorado course #DrRussCohen 💎 💎If serum CMV PCR neg, it’s not CMV colitis 💎Fever of unknown origin - Think CMV & Histo sp if on TNFi or JAKi 💎Zoster risk 6-8% w AZA & JAKi ->vaccinate! 💎QFT indeterminate: if CxRay neg, no RF: it’s not TB! start IBD Rx

🤩 to start 3-year study funded @HelmsleyTrust on 'GLP-1R Agonists to Promote Epithelial Healing in Crohn’s disease' with #LouisCohen @AndresYarur @WashUMedGastro @WashUMedIBD @MSHS_IBDCenter @IBDCedarsSinai @P_DeepakIBDLab with detailed metabolic analyses mountsinai.org/about/newsroom…

The hepatitis B vaccine is amazing. It also has a wild backstory Want to hear it? A #tweetorial 1/ #livertwitter #MedTwitter

How to resmetirom Practice guidelines from @AASLDtweets led by @MichiganLiver’s own Vincent Chen Open access: pdfs.journals.lww.com/hep/9900/resme…

🌟 Dietary therapy in Eosinophilic Esophagitis 🌟 Top-down vs Step-up approaches Image courtesy: mdpi.com/2072-6643/13/5…

Should we provide anticoagulation in ambulatory patients with active #IBD ? A review of the evidence ✅not cost effective to anticoagulate all ✅not all patients have same risk ✅thrombosis is clearly ⬆️on steroids Other questions would be if we do, for how long? Which anticoagulant? @my_ueg #UEG2024

Which drugs to combine if we consider a dual therapy to treat #IBD EIMS/IMIDs? wonderful review by @TrianaLobaton about the evidence of dual therapy ✅consider MOAs to avoid overlapping ‼️off label ,careful monitoring ✅diet & exercise to be considered too! ✅Always MDT decision on drug & doses @my_ueg #UEG2024